Navigation Links
ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
Date:9/11/2009

LEUVEN, Belgium, September 11 /PRNewswire-FirstCall/ --

- ThromboGenics' Significant Achievements Over the Last Year are Recognised in Nominations

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announced today that it has been shortlisted for both the "Biotech Company of the Year" and "Licensing Deal of the Year" awards at the Scrip Awards 2009. These nominations recognise the transformational year that ThromboGenics has had, and the progress it has made toward becoming a profitable, integrated Company focused on cutting edge ophthalmic medicines.

The Biotech Company of the Year award recognises the progress and achievement a biotech company has made within the last twelve months. During the period, ThromboGenics has started the pivotal transatlantic Phase III programme with microplasmin for back of the eye disease, signed a EUR500 million partnership deal with Roche for its novel anti-cancer antibody TB-403, and moved its novel anti-coagulant TB-402 into Phase II trials. TB-402 is another potential partnership opportunity. There are four other companies nominated in this category.

The Licensing Deal of the Year award acknowledges the achievement of a Company in signing a licensing deal that has both monetary and strategic benefits to all parties. ThromboGenics signed a major partnership deal with Roche for TB-403 under which the Company and co-development partner BioInvent received an upfront payment of EUR50 million, an additional EUR450 million in potential milestones, and double digit royalties on future product sales. There are four other licensing deals nominated in this category.

The Scrip Awards is one of the biotechnology and pharmaceutical industry's most prestigious and highly contested awards event. The event is in its fif
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Indianapolis, IN (PRWEB) , ... July 01, 2015 , ... ... the 2015 BIO International Convention in Philadelphia, PA. , The presentation took ... milestones and outlined the plans for the development of APX3330 for the treatment of ...
(Date:6/30/2015)... ... 2015 , ... Students and faculty from Beijing City University ... “Integrative Biotechnology,” an applied biotechnology course team-taught by faculty members from both institutions. ... from both universities and is taught on both continents. , “Our alliance with ...
(Date:6/30/2015)... , June 30, 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: ... on developing therapeutics that address unmet medical needs ... George Elston will present at the Cantor ... July 8, 2015Time: , 4:45 PM EDTLocation: , ... & archive): , www.juniperpharma.com, under  ,Investor, ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... to the federal government, announced in a paper published this week in the ... potential problem with the diagnostic techniques currently used to detect the Ebola virus. ...
Breaking Biology Technology:Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4
... the Battle of Britain in 1940, Prime Minister Winston Churchill ... air power by saying, "Never in the field in human ... few." , ,If Churchill was around to describe the July ... of Assembly Speaker John Gard, he might have said, "Never ...
... slows. Indeed, in Europe, where I find myself this week, ... will last until the first of September. People relax. The ... , ,Or does it? , ,After a rare weekend away ... my inbox and a to-do list that had miraculously grown ...
... - A company that uses Medical College of ... awarded $2.5 million for development of diagnostics for sepsis ... said the research grant, which will come over the ... molecular biological methods, miniaturize those methods, and demonstrate the ...
Cached Biology Technology:Delivery of needles in the Capitol missed the point about stem-cell research 2Delivery of needles in the Capitol missed the point about stem-cell research 3Leaving it all behind 2
(Date:6/16/2015)... 16, 2015 /CNW Telbec/ - handyem Inc. and ... the incorporation of handyem,s HPC-150 portable flow cytometer ... Mo-POD™. This unprecedented model of mobile laboratory platform ... the Pennsylvania Convention Center, ... th to 18 th 2015.  By ...
(Date:6/16/2015)... 2015 Fingerprint Cards has received an ... the company,s portfolio from one of its module partners in ... take place during the third quarter 2015. The sensors will ... . Jörgen Lantto, CEO of FPC, comments: " ... growing interest from smartphone OEMs in integrating touch fingerprint sensors ...
(Date:6/15/2015)... 2015 According to a new ... (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern ... by MarketsandMarkets, The Natural Language Processing Market is expected ... 18.4% for the forecast period 2015-2020. ... igures spread   through 155 P ages ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
... NOAA scientists report the discovery of the first known colony of ... A report on the discovery was published last month in the ... name due to its flat-topped, table-like shape, table coral ( Acropora ... of the tropical Pacific, but it has never been observed in ...
... online by the Nature journal Leukemia suggests ... some types of leukemia resist treatment can increase the ... Cincinnati Children,s Hospital Medical Center report that their experimental ... along with chemotherapy was particularly effective at stopping ...
... Calif. , Aug. 8, 2013 The radio frequency ... moving slowly mainly due to high costs and the criticality ... related to food safety and drug traceability in the U.S. ... into the market. New analysis from Frost & ...
Cached Biology News:Study suggests way to fight therapy resistant leukemia by blocking DNA repair 2Study suggests way to fight therapy resistant leukemia by blocking DNA repair 3Frost & Sullivan: Government Mandates Create Momentum in Uptake of Radio Frequency Identification in Global Cold Chain 2Frost & Sullivan: Government Mandates Create Momentum in Uptake of Radio Frequency Identification in Global Cold Chain 3Frost & Sullivan: Government Mandates Create Momentum in Uptake of Radio Frequency Identification in Global Cold Chain 4
Human Cell Line Slides...
... Level 2 Detection System combines the ... bonding principle and Signets unique formulation ... specificity and reliablility. Signet reagents will ... manual and automated protocols. ,Signets USA ...
... Signet Level 2 Detection System combines ... chemical bonding principle and Signets unique ... sensitivity, specificity and reliablility. Signet reagents ... both manual and automated protocols. ...
XPMC2H Immunogen: XPMC2H (NP_065118, 323 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: